Century Therapeutics, Inc. (NASDAQ: IPSC) is a Healthcare company (Biotechnology) with a market capitalization of $249M. The Maz Rating grades it against the other companies in its sector.
Century Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.37, Century Therapeutics, Inc. trades at 1.3x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -45.6%, return on invested capital of -42.7% and a free cash flow yield of -34.5%. On the balance sheet: a debt-to-equity ratio of 0.18 and a current ratio of 8.74. Over the past 52 weeks the share price ranged from $0.45 to $3.04, with a beta of 1.77.
Century Therapeutics, Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 7 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Century Therapeutics, Inc. (IPSC) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 48.8% / 30% · Interest income / Revenue 175300000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 32.9% / 33% · Receivables / Mkt Cap (36m) 0.34% / 49% · Interest income / Revenue 175300000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 32.9% / 33.33% · Receivables / Mkt Cap (24m) 0.34% / 33.33% · Interest income / Revenue 175300000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 4.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 44.4% / 33.33% · Receivables / Avg Assets (4Q) 0.17% / 33.33% · Interest income / Revenue 175300000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 44.6% / 33.33% · (Cash+Recv) / Total Assets 45.1% / 33.33% · Interest income / Revenue 175300000.0% / 5% | Fail |
No. As of September 2026, Century Therapeutics, Inc. (IPSC) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Century Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 175300000.0% of each dividend: Century Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.